Immunogenetics - Disease and pharmacogenetics HLA association testing

TIS provides testing for patients to determine if they have HLA alleles defining genetic susceptibility with diseases or hypersensitivities to certain drugs. The presence or absence of the HLA allele can affect the clinical management of the patient. Confirmatory HLA typing is recommended for pharmacogenetic HLA associations due to the risk to the patient.

Well-documented HLA allele associations with these diseases and pharmacogenetic hypersensitivities can be invoiced through the Medicare schedule in some states (VIC, NSW). Testing for disease associations or drug hypersensitivities that are not eligible for Medicare invoicing is subject to written informed financial consent from the patient.

For patients that are part of a clinical trial, refer to the TIS External Clinical Trials and Research page for further information.

Refer to the tables below for well-documented HLA allele associations with diseases and drug sensitivities. For testing outside the below list, please contact the relevant laboratory.